Tirzepatide goes a step further by also targeting glucose-dependent insulinotropic polypeptide (GIP) another gut-derived incretin hormone with complementary but distinct effects
The gastrointestinal side effects (oily stools, flatulence, fecal urgency) are well-documented and directly tied to dietary fat intake
A randomized study in Diabetes Care (PMC10154650) confirms that tirzepatide significantly cuts fat mass and appetitebut daily habits like emotional snacking can still counteract progress
Simultaneously, tirzepatide's GLP-1 receptor agonist activity promotes glucose-dependent insulin secretion, inhibits glucagon release, and may influence gastric emptying in experimental settings
Understanding why tirzepatide burning at injection site occurs and implementing proper injection techniques can significantly improve patient comfort and treatment adherence
Tirazepatide is unique as it targets both the GIP and GLP-1 receptor agonists